Page last updated: 2024-08-21

oxazoles and Hypertrophy, Right Ventricular

oxazoles has been researched along with Hypertrophy, Right Ventricular in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Haga, S; Hamano, T; Hirai, T; Ishizaka, Y; Mimori, A; Tsuchiya, H	1

Other Studies

1 other study(ies) available for oxazoles and Hypertrophy, Right Ventricular

Article	Year
A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression. Experimental lung research, 2015, Volume: 41, Issue:1 Topics: Angiotensin-Converting Enzyme 2; Animals; Caveolin 1; Drug Evaluation, Preclinical; Enzyme Activation; Feedback, Physiological; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Janus Kinases; Male; Monocrotaline; Oxazoles; Peptidyl-Dipeptidase A; Pyrimidines; Rats, Sprague-Dawley; STAT Transcription Factors; Transforming Growth Factor beta	2015

Article

Year

A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression.

Experimental lung research, 2015, Volume: 41, Issue:1

Topics: Angiotensin-Converting Enzyme 2; Animals; Caveolin 1; Drug Evaluation, Preclinical; Enzyme Activation; Feedback, Physiological; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Janus Kinases; Male; Monocrotaline; Oxazoles; Peptidyl-Dipeptidase A; Pyrimidines; Rats, Sprague-Dawley; STAT Transcription Factors; Transforming Growth Factor beta

2015